📊 OKUR Key Takeaways
Is OnKure Therapeutics, Inc. (OKUR) a Good Investment?
OnKure Therapeutics exhibits classic pre-commercial biotech fundamentals: minimal $3.4M revenue against a massive $63M operating loss, yielding an operating margin of -1833%. While the $59M cash position and zero debt provide near-term runway (~1.1 years at current burn), the company's sustainability depends entirely on unproven drug development success with no visible path to profitability. The 71% YoY EPS improvement signals reduced losses but remains far from breakeven.
OnKure shows minimal revenue alongside extremely negative margins and substantial cash burn, consistent with a pre-commercial biotech profile. The debt-free balance sheet and strong liquidity are positives, but the current cash level covers roughly a year of operations at the present burn rate, implying a high likelihood of future financing or dilution absent meaningful, recurring revenue.
Why Buy OnKure Therapeutics, Inc. Stock? OKUR Key Strengths
- Strong cash position ($59M) provides 12+ months operational runway
- Zero debt with healthy balance sheet ($56.2M equity vs $5.9M liabilities)
- Excellent liquidity (10.28x current ratio) reduces near-term solvency risk
- Strong cash position and 10.28x current ratio
- Debt-free capital structure (0.00x D/E)
- Minimal capex needs, preserving operational flexibility
OKUR Stock Risks: OnKure Therapeutics, Inc. Investment Risks
- Unsustainable cash burn rate (-$51.8M annually) with only 1.1-year runway before capital raise likely required
- Minimal revenue ($3.4M) against massive R&D spend indicates pre-commercialization stage with unproven drug candidates and significant execution risk
- Severe margin profile (-1733.7% net margin) typical of biotech but requires successful clinical outcomes and regulatory approval for turnaround
- High dilution risk if capital raise becomes necessary; pharma pipeline success rate inherently low
- Severe operating and net losses with deeply negative margins
- Short cash runway (~12 months) implying dilution/financing risk
- Low and potentially non-recurring revenue, limited visibility
Key Metrics to Watch
- Cash burn trend and runway extension (any slowdown in operating cash outflow)
- Pipeline progress and clinical trial milestones (regulatory approvals or partnership announcements)
- Revenue growth rate upon product commercialization
- Quarterly operating cash burn and remaining cash runway
- Recurring revenue growth and operating margin trend
OnKure Therapeutics, Inc. (OKUR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.28x current ratio provides a solid financial cushion.
OKUR Profit Margin, ROE & Profitability Analysis
OKUR vs Healthcare Sector: How OnKure Therapeutics, Inc. Compares
How OnKure Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OnKure Therapeutics, Inc. Stock Overvalued? OKUR Valuation Analysis 2026
Based on fundamental analysis, OnKure Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OnKure Therapeutics, Inc. Balance Sheet: OKUR Debt, Cash & Liquidity
OKUR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: OnKure Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-15.28 indicates the company is currently unprofitable.
OKUR Revenue Growth, EPS Growth & YoY Performance
OnKure Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
OKUR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OnKure Therapeutics, Inc. (CIK: 0001637715)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_070404.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_070438.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_070422.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_070420.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_090435.xml | View → |
❓ Frequently Asked Questions about OKUR
What is the AI rating for OKUR?
OnKure Therapeutics, Inc. (OKUR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OKUR's key strengths?
Claude: Strong cash position ($59M) provides 12+ months operational runway. Zero debt with healthy balance sheet ($56.2M equity vs $5.9M liabilities). ChatGPT: Strong cash position and 10.28x current ratio. Debt-free capital structure (0.00x D/E).
What are the risks of investing in OKUR?
Claude: Unsustainable cash burn rate (-$51.8M annually) with only 1.1-year runway before capital raise likely required. Minimal revenue ($3.4M) against massive R&D spend indicates pre-commercialization stage with unproven drug candidates and significant execution risk. ChatGPT: Severe operating and net losses with deeply negative margins. Short cash runway (~12 months) implying dilution/financing risk.
What is OKUR's revenue and growth?
OnKure Therapeutics, Inc. reported revenue of $3.4M.
Does OKUR pay dividends?
OnKure Therapeutics, Inc. does not currently pay dividends.
Where can I find OKUR SEC filings?
Official SEC filings for OnKure Therapeutics, Inc. (CIK: 0001637715) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OKUR's EPS?
OnKure Therapeutics, Inc. has a diluted EPS of $-4.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OKUR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, OnKure Therapeutics, Inc. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OKUR stock overvalued or undervalued?
Valuation metrics for OKUR: ROE of -105.9% (sector avg: 15%), net margin of -1,733.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OKUR stock in 2026?
Our dual AI analysis gives OnKure Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OKUR's free cash flow?
OnKure Therapeutics, Inc.'s operating cash flow is $-51.8M, with capital expenditures of $46.0K. FCF margin is -1,511.0%.
How does OKUR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,733.7% (avg: 12%), ROE -105.9% (avg: 15%), current ratio 10.28 (avg: 2).